Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Vogt

Showing results (271-280 of 291) with videos related to

Pageof 30
Sort By:
Neuron|July 19, 2020
Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune ActivationHyeseung Lee, Robert J Fenster, S Sebastian Pineda, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2007
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation patternChristian Hafner, Elena López-Knowles, Nuno M Luis, et al.
The Journal of Investigative Dermatology|October 26, 2013
SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathwayTao Wang, Yingbin Ge, Min Xiao, et al.
The Lancet. Oncology|May 11, 2016
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trialUlrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Plos Pathogens|June 23, 2017
Identification of C/EBPα as a novel target of the HPV8 E6 protein regulating miR-203 in human keratinocytesAnna M Marthaler, Marta Podgorska, Pascal Feld, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2010
Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumorsChristian Hafner, Agustí Toll, Alejandro Fernández-Casado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanomaAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2019
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel NodeUlrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|November 7, 2009
Screening for iron overload: lessons from the hemochromatosis and iron overload screening (HEIRS) studyPaul Adams, James C Barton, Gordon D McLaren, et al.
Pageof 30

Showing results (271-280 of 291) with videos related to

Sort By:
Pageof 30
Neuron|July 19, 2020
Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune ActivationHyeseung Lee, Robert J Fenster, S Sebastian Pineda, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2007
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation patternChristian Hafner, Elena López-Knowles, Nuno M Luis, et al.
The Journal of Investigative Dermatology|October 26, 2013
SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathwayTao Wang, Yingbin Ge, Min Xiao, et al.
The Lancet. Oncology|May 11, 2016
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trialUlrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Plos Pathogens|June 23, 2017
Identification of C/EBPα as a novel target of the HPV8 E6 protein regulating miR-203 in human keratinocytesAnna M Marthaler, Marta Podgorska, Pascal Feld, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2010
Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumorsChristian Hafner, Agustí Toll, Alejandro Fernández-Casado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanomaAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2019
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel NodeUlrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|November 7, 2009
Screening for iron overload: lessons from the hemochromatosis and iron overload screening (HEIRS) studyPaul Adams, James C Barton, Gordon D McLaren, et al.
Pageof 30